Prolia denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for prolia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Prolia as Experimental

An experimental or investigational denial for Prolia (denosumab) is uncommon given its FDA-approved status, but it may occur when Prolia is requested for an indication that UnitedHealthcare's coverage policy classifies as not yet established — such as a less common bone-loss condition, a pediatric population, or a specific oncology-related indication that the plan has not yet incorporated into its standard coverage criteria. The plan is asserting that the evidence base for the specific use is insufficient by its internal standards.

## Why This Denial Is Appealable

FDA approval is strong evidence that an agent is not experimental for its approved indications. If Prolia is being prescribed for an FDA-approved indication, the experimental classification contradicts the regulatory record and should be directly challenged. Even for off-label uses, major professional society guidelines (such as those from the American Society for Bone and Mineral Research or relevant oncology bodies) can establish that a use is within the accepted standard of care — a standard that plans must generally apply in experimental/investigational determinations. External reviewers apply independent clinical-evidence standards and regularly reverse these denials.

## Federal Appeal Framework

• Internal appeal (ACA §2719): File a full internal appeal. Request in writing the specific UHC policy under which the use was classified as experimental, including the evidence standards the plan applies.
• ERISA §503: For employer-sponsored plans, ERISA entitles you to the full claims file and all evidence cited in the denial, including the version of UHC's coverage policy applied.
• External review: Experimental/investigational denials are specifically eligible for ACA §2719 external review. Independent reviewers apply clinical-evidence standards that may differ from UHC's internal criteria, and reversals on this basis are common when guidelines support the use.
• Timeline: External review requests are typically due within four months of the final adverse internal decision. Expedited review is available when delay seriously jeopardizes health.

## Documents to Gather

• FDA labeling: The current FDA-approved prescribing information for Prolia, highlighting the specific approved indication that matches the patient's diagnosis. Obtain this directly from the FDA label or manufacturer.
• Applicable guideline citations: References from the relevant professional society guideline organization (do not cite specific statistics or trial names — cite the organization and guideline title, and obtain the exact current recommendation from the guideline itself).
• Prescriber medical-necessity letter: A detailed letter from the treating clinician explaining that the use is within the standard of care, citing the applicable guideline organization, and addressing UHC's specific experimental-classification criteria.
• Diagnosis documentation: Chart notes confirming the diagnosis and clinical context that match the FDA-approved or guideline-supported indication.
• UHC experimental/investigational policy: Obtain the exact UHC coverage policy for Prolia, including the evidence criteria the plan uses to classify uses as experimental.

## Criteria-Mapping Structure

Address the experimental classification head-on: identify the FDA approval status for the indication, identify the relevant guideline organization's position, and map each of UHC's experimental-criteria requirements to the supporting evidence. If the policy applies an evidence tier system, identify which tier the use falls into under the plan's own framework and provide the evidence supporting that classification.